<P>&nbsp;</P> <P align=justify><STRONG>The company based in Lyon develops drug candidates to clinical proof-of-concept before seeking <A title="" href="https://www.aderly.com/pharmaceutique_biotech/index,p,100044,EN.jsp" target=_blank>pharmaceutical industry partners</A></STRONG>. Poxel was spun out from Merck Serono and in 2010 has raised &#8364;16 million through a Series A round. It operates independently as a lean organization with strong in-house drug development expertise.</P> <P align=justify><BR>Poxel&#8217;s product pipeline consists of several first-in-class Type 2 diabetes products, including Imeglimin in Phase II development. Recently, Imeglimin has also shown significant clinical benefits in Type 2 diabetes, when added to sitagliptin. The Phase II study achieved the primary and secondary endpoints. </P> <P align=justify><BR><STRONG>December 18, Poxel SA announced a &#8364;13 million fund raising in a Series B round</STRONG>. The financing was led by Edmond de Rothschild Investment Partners (EdRIP) and included all existing investors: InnoBio fund managed by CDC Entreprises within FSI France Investment program; and Omnes Capital (formerly Cr&#233;dit Agricole Private Equity). <STRONG>A significant part of the funds will be used to confirm efficacy data of the company&#8217;s lead program, Imeglimin, a novel anti-diabetic agent.</STRONG></P> <P align=justify><BR>Source: <A title="" href="http://www.lyonbiopole.com/index-en.html" target=_blank>Lyonbiop&#244;le</A><BR></P>